🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficacy of Aponeurectomy on the 2-year Recurrence Rate of Dupuytren's Disease

RecruitingNAAges 18 Years - anyAllElsan
NCT05067764 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Dupuytren's disease is a frequent hereditary disease in Northern Europe. It is a degenerative disease affecting the palmar aponeurosis of the hand. It develops a progressive contractile fibrosis which cuts the hypodermic fatty tissue, adheres to the skin and the phalanges, gradually bending the affected rays, resulting in significant functional impotence. Various medical and surgical treatments are available.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Carrier of Tubiana stage II-IV Dupuytren's disease on at least one or more rays, not previously operated * Indication of a surgery by aponeurectomy * Skin pinch of the posterior aspect of the arm of more than 1cm * Affiliation to a social security system * Patient informed of the study and having given informed consent Exclusion Criteria: * Previous surgery of any kind for Dupuytren's disease * Involvement on the thumb only * Need for a total skin graft or a pedicle flap on all the rays to be treated * Active autoimmune disease * Previous treatment with collagenase * Pregnant and breastfeeding women * Patient under legal protection * Contraindications to MRI (criteria applicable only for patients from the coordinating center, not applicable for other centers)
💊

What it tests

  • Aponeurectomy with grafting
  • Aponeurectomy alone
📍

Where

2 sites
Institut Aquitain de la Main
Pessac, France
Santé Atlantique ELSAN
Saint-Herblain, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy